Gilead Sciences, Inc.
An insider at 2 companies in coverage, as reported on Form 4. SEC CIK 882095. Latest Form 4 filed Feb 21, 2025.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| Arcus Biosciences, Inc.RCUS | 10% owner | 4 | 2021-01-31 | 2025-02-18 |
| Kalaris Therapeutics, Inc.KLRS | 10% owner | 1 | 2023-06-27 | 2023-06-27 |
Transactions: 5
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-02-18 | Arcus Biosciences, Inc.10% owner | Purchase | 1,363,636 | $11.00 | $15.0m | Form 4 |
| 2024-01-29 | Arcus Biosciences, Inc.10% owner | Purchase | 15,238,095 | $21.00 | $320.0m | Form 4 |
| 2023-06-28 | Arcus Biosciences, Inc.10% owner | Purchase | 1,010,000 | $19.26 | $19.5m | Form 4 |
| 2023-06-27 | Kalaris Therapeutics, Inc.10% owner | Purchase | 2,930,870 | $3.75 | $11.0m | Form 4 |
| 2021-01-31 | Arcus Biosciences, Inc.10% owner | Purchase | 5,650,000 | $39.00 | $220.3m | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 30, 2026, 11:45 ET. Listed shows no prices and gives no investment advice.